Xiamen Amoytop Biotech Co., LTD.
Research Xiamen Amoytop Biotech Co., LTD. (688278.SS) on Bullrun: market cap CNY 17.76B, P/E 21.2, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker688278.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCNY
- Market capCNY 17.76B
- P/E21.2
- Dividend yield1.4%
- Financial periodQ2 2026
- RevenueCNY 1.04B
- Net incomeCNY 312.03M
- Free cash flowCNY 132.16M
- Gross margin88.5%
Valuation Snapshot
latest market cap is CNY 17.76B; P/E is 21.2; dividend yield is 1.4%.
Peer valuation comparison
Latest P/E is 21.22x versus a Healthcare sector median of 21.8x (2.6% below).
Latest dividend yield is 1.43% versus a Healthcare sector median of 2.4% (40.4% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 17.76B | 21.2 | 1.4% | 0.62 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.62 CNY, yield 1.4%.
About Xiamen Amoytop Biotech Co., LTD.
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.
ETFs that hold Xiamen Amoytop Biotech Co., LTD.
US-listed ETFs
Xiamen Amoytop Biotech Co., LTD. is held by 15 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
Portfolios as filed with the SEC on Form N-PORT, dated June to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xiamen Amoytop Biotech Co., LTD.'s market cap?
Xiamen Amoytop Biotech Co., LTD.'s market capitalization is CNY 17.76B.
What is Xiamen Amoytop Biotech Co., LTD.'s P/E ratio?
Xiamen Amoytop Biotech Co., LTD.'s price-to-earnings (P/E) ratio is 21.2.
Does Xiamen Amoytop Biotech Co., LTD. pay a dividend?
Xiamen Amoytop Biotech Co., LTD. has a dividend yield of 1.4%.
What does Xiamen Amoytop Biotech Co., LTD. do?
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.